Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials | Zendy

Rekha R. Rapaka | Zendy; E. Adrianne Hammershaimb | Zendy; Kathleen M. Neuzil | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials

Author(s) -

Rekha R. Rapaka,

E. Adrianne Hammershaimb,

Kathleen M. Neuzil

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab213

Subject(s) - vaccine efficacy , covid-19 , medicine , clinical trial , vaccine trial , gold standard (test) , intensive care medicine , population , placebo , randomized controlled trial , viewpoints , disease , immunology , alternative medicine , vaccination , infectious disease (medical specialty) , environmental health , pathology , art , visual arts

Coronavirus disease 2019 (COVID-19) vaccine trials provide valuable insight into the safety and efficacy of vaccines, with individually randomized, placebo-controlled trials being the gold standard in trial design. However, a myriad of variables must be considered as clinical trial data are interpreted and used to guide policy decisions. These variables include factors such as the characteristics of the study population and circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains, the force of infection, the definition and ascertainment of endpoints, the timing of vaccine efficacy assessment, and the potential for performance bias. In this Viewpoints article, we discuss critical variables to consider when comparing efficacy measurements across current and future COVID-19 vaccine trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research